Athenex Announces FDA Acceptance for Filing of U.S. NDA for Oral Paclitaxel and Encequidar in Metastatic Breast Cancer with Priority Review
FDA grants Priority Review and sets PDUFA target action date of February 28, 2021FDA indicated that it is not currently […]